Market Overview on Survival Motor Neuron ProteinComponent Of Gems 1 -Pipeline Review, H1 2016

Survival Motor Neuron ProteinComponent Of Gems 1 or Gemin-1 or SMN1 or SMN2-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted pipeline therapeutics.

The report provides comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Survival Motor Neuron ProteinComponent Of Gems 1 or Gemin-1 or SMN1 or SMN2-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted therapeutics

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AveXis, Inc. Bioblast Pharma Ltd. F. Hoffmann-La Roche Ltd. Genethon Genzyme Corporation Ionis Pharmaceuticals, Inc. Novartis AG Sarepta Therapeutics, Inc. Voyager Therapeutics, Inc. WAVE Life Sciences Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###